Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03265652
Other study ID # LUM-VBU-IPL-M22-17-02
Secondary ID 0171-17-SZMC
Status Completed
Phase N/A
First received
Last updated
Start date May 15, 2018
Est. completion date April 18, 2019

Study information

Verified date February 2020
Source Lumenis Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the current study is to examine the contribution of intense pulsed light (IPL) for relieving signs and symptoms of dry eye due to meibomian gland dysfunction. The effect of IPL will be examined in a study designed as a randomized controlled trial. In the study arm, subjects will undergo 4 treatment sessions, consisting of IPL pulses immediately followed by expression of the meibomian glands. In the control arm, subjects will undergo the same treatments, except that the IPL pulses will be disabled. For each subject, the duration of the study will be 10 weeks, as explained in the detailed description,


Description:

Outcome measures (tear break-up time, tear film osmolarity, meibomian gland assessment, number of meibomian glands yielding liquid secretion in lower eyelid , meibography, self-assessed symptoms and close up photos of the lid margins) will be measured at baseline. All subjects will receive 4 treatments at 2 weeks intervals. In each treatment session, a subject allocated to the study group will be treated with IPL administered in the malar region, from tragus to tragus including the nose, 2-3 mm below the lower eyelids. Immediately following the IPL administration, the meibomian glands will be manually expressed from both eyelids. Subjects in the control arm will receive exactly the same treatment, except that the IPL administration will be sham. A single follow-up will occur at 10 weeks after the baseline (or 4 weeks after the 4th treatment session). At the follow-up, the changes in the outcome measures will be evaluated, and compared between the two arms.

For each subject, the duration of the study will be 10 weeks: 1st treatment at baseline; 2nd treatment at 2 weeks after baseline; 3rd treatment at 4 weeks after baseline; 4th treatment at 6 weeks after baseline; and a single follow-up at 10 weeks after baseline).

Statistically significant differences between the two arms will support the study hypothesis that IPL treatment itself provides relief to both signs and symptoms of dry eye disease.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date April 18, 2019
Est. primary completion date April 18, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject is able to read, understand and sign an Informed Consent (IC) form

2. Subject is 18 years or older

3. Subject has Fitzpatrick skin type I to IV

4. SPEED questionnaire equal or more than 10

5. OSDI questionnaire equal or more than 23

6. In both eyes, at least 5 non-atrophied meibomian glands on the lower eyelid.

7. In both eyes, Tear break up time equal or less than 7 seconds

8. In both eyes, MGA (the total meibomian gland score for 15 glands of the lower eyelid) is smaller or equal to 12

Exclusion Criteria:

1. Contact lens wear within the month prior to screening

2. Unwilling to discontinue use of contact lenses for the duration of the study

3. Ocular surgery or eyelid surgery within 6 months prior to screening

4. Neuro-paralysis in the planned treatment area within 6 months prior to screening

5. Other uncontrolled eye disorders affecting the ocular surface, for example active allergies

6. Current use of punctal plugs

7. Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area

8. Uncontrolled infections or uncontrolled immunosuppressive diseases

9. Subjects with ocular infections within 6 months prior to screening

10. Prior history of cold sores or rashes in the perioral area or in the planned treatment area that could be stimulated by light at a wavelength of 560 nm to 1200 nm (e.g., Herpes simplex 1 & 2, Systemic Lupus erythematosus, porphyria)

11. Use of photosensitive medication and/or herbs that may cause sensitivity to 560-1200 nm light exposure, such as Isotretinoin, Tetracycline, Doxycycline, or St. John's Wort within 3 months prior to screening

12. Over exposure to sun within 4 weeks prior to screening, in the judgment of the investigator

13. Administration of prescription eye drops for dry eye within 7 days prior to screening, excluding artificial tears and glaucoma drops

14. Radiation therapy to the head or neck within 12 months prior to screening, or planned radiation therapy within 8 weeks after completion of all IPL treatments

15. Treatment with chemotherapeutic agent within 8 weeks prior to screening, or planned chemotherapy within 8 weeks after completion of all IPL treatments

16. New topical treatments within the area to be treated, or oral therapies within 3 months prior to screening, except over-the-counter acetaminophen-based analgesics (such as Extra Strength Tylenol®) for pain management after study treatment, new oral omega 3 fatty acid supplements and topical artificial tears

17. Change in dosage of any systemic medication within 3 months prior to screening

18. Anticipated relocation or extensive travel outside of the local study area preventing compliance with follow-up over the study period

19. Legally blind in either or both eyes

20. History of migraines, seizures or epilepsy

21. IPL treatment within 12 months prior to screening

22. Lipiflow treatment, or any other thermal treatment of the eyelids, within 6 months prior to screening

23. Expression of the meibomian glands within 6 months prior to screening

24. Any condition revealed during the eligibility screening process whereby the investigator deems the subject inappropriate for this study

25. Women below the age of menopause (50 years of age)

Study Design


Intervention

Device:
Intense Pulsed Light (IPL) therapy
Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
Sham therapy
Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.

Locations

Country Name City State
Israel Shaare Zedek Jerusalem

Sponsors (1)

Lead Sponsor Collaborator
Lumenis Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other Change from baseline MGYLS Change of the number of meibomian glands yielding liquid secretion, from baseline to the follow-up 10 weeks
Other Change from baseline TFO Change of the tear film osmolarity, from baseline to the follow-up 10 weeks
Other Change from baseline Meiboscore Change of the Meiboscore evaluated with meibography, from baseline to the follow-up 10 weeks
Other Percentage of study eyes with normal TBUT Percentage of study eyes with TBUT > 10 seconds at the follow-up 10 weeks
Other Percentage of subjects with normal OSDI Percentage of subjects with OSDI < 23 at the follow-up 10 weeks
Other Percentage of subjects with normal MGA Percentage of eyes with MGA > 12 at the follow-up 10 weeks
Other Qualitative assessment of eyelid appearance High resolution photos of the upper and lower eyelids in both eyes 10 weeks
Primary Change of baseline TBUT Change of Tear break up time in the study eye, from baseline to follow-up 10 weeks
Secondary Change from baseline MGA Change of Meibomian gland secretion score, from baseline to follow-up, in both eyes 10 weeks
Secondary Change from baseline OSDI Change of self-assessed symptoms with the OSDI questionnaire, from baseline to follow-up, in both eyes 10 weeks
See also
  Status Clinical Trial Phase
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A